Astellas Proposes to Acquire CV Therapeutics for $1B

This post was commissioned on January 27, 2009, and it was categorized as Uncategorized.

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

Astellas announced that it has submitted a proposal to the Board of Directors of CV Therapeutics to acquire all outstanding common shares of CV Therapeutics for $16.00 per share in cash. The proposal represents a 41% premium to the closing share price of CV Therapeutics on January 26, 2009, and a 69% premium to CV Therapeutics’ 60-day average closing price. The proposal is not subject to any financing condition and represents a total equity value of $1.0 billion on a fully diluted basis.

This proposal was previously submitted to the Board of Directors of CV Therapeutics in a letter dated November 14, 2008 and Astellas was informed on November 21, 2008 that the CV Therapeutics Board had rejected the proposal. CV Therapeutics has subsequently declined to engage Astellas in any meaningful discussions regarding a transaction.

I don’t blame CVT for not jumping at this offer or Astellas for making it. Astellas wants a piece of Ranexa (some people project it’s on pace to top $400M in sales within 5 years) and CV Therapeutics doesn’t want to give it up. Judging by the market’s response (already trading at $17/share in the pre-market).

My best guess, Astellas sweetens the bid to [licks index finger and sticks it above his head]… $21/share

Astellas Proposes to Acquire CV Therapeutics for $16 Per Share in Cash

Theoretically Related Posts

February 27, 2009 -- They Weren’t Bluffing: Astellas Lauches Tender Offer for CV Therapeutics (0)
March 12, 2009 -- CV Tells Astellas to Shove It: Looks to Gilead (0)
November 14, 2008 -- BBM Offers to Acquire YM BioSciences for $29M (0)
October 23, 2008 -- No Rumors For You. Come Back. One Year (0)
August 22, 2008 -- King Tenders All Cash $1.4B Unsolicited Bid For Alphama (0)
July 23, 2008 -- Roche on Spending Spree (0)
May 16, 2008 -- Rumor Mill: Pfizer Buying MediGene? (2)
May 14, 2008 -- Intercell AG Strengthens Vaccine Business (0)
April 25, 2008 -- Astellas Pharma and CoMentis Sign $760M Alzheimer’s Deal (1)
April 22, 2008 -- GlaxoSmithKline Buys Sirtris for $720M (3)

This post was constructed by

Eben Tessari

.

Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.

If one were so inclined, one could follow him at any of these fine web 2.0 establishments: